357 filings
Page 6 of 18
3
Helen Katrina Tayton-martin
4 Jan 21
Trillium Therapeutics / HELEN KATRINA TAYTON-MARTIN ownership change
8:08pm
S-8
TRIL
Trillium Therapeutics Inc.
10 Dec 20
Registration of securities for employees
4:05pm
6-K
TRIL
Trillium Therapeutics Inc.
7 Dec 20
Trillium Therapeutics Presented Clinical Data at the 62ND Ash Annual Meeting and Provides Guidance for 2021
4:05pm
6-K
TRIL
Trillium Therapeutics Inc.
25 Nov 20
Trillium Therapeutics to Present Clinical Data at the 62ND American Society of Hematology Annual Meeting
7:03am
6-K
TRIL
Trillium Therapeutics Inc.
16 Nov 20
Consolidated Financial Statements
7:09am
6-K
TRIL
Trillium Therapeutics Inc.
12 Nov 20
Trillium Therapeutics Appoints Paolo Pucci
4:05pm
6-K
TRIL
Trillium Therapeutics Inc.
2 Nov 20
Trillium Therapeutics Announces Formation of Scientific Advisory Board
4:15pm
6-K
TRIL
Trillium Therapeutics Inc.
5 Oct 20
Trillium Therapeutics Receives Notices of Allowance from U.S. Patent and Trademark Office
7:14am
6-K
TRIL
Trillium Therapeutics Inc.
18 Sep 20
Trillium Therapeutics Appoints Michael Kamarck, PH.D., to Its Board of Directors
7:19am
6-K
TRIL
Trillium Therapeutics Inc.
16 Sep 20
Trillium Closes US$150 Million Public Offering of Common Shares
4:30pm
424B5
TRIL
Trillium Therapeutics Inc.
11 Sep 20
Prospectus supplement for primary offering
4:45pm
6-K
TRIL
Trillium Therapeutics Inc.
11 Sep 20
Trillium Announces Pricing of US$130 Million Public Offering of Common Shares
12:00am
424B5
TRIL
Trillium Therapeutics Inc.
9 Sep 20
Prospectus supplement for primary offering
4:15pm
6-K
TRIL
Trillium Therapeutics Inc.
9 Sep 20
Trillium Announces Proposed Public Offering of Common Shares
4:01pm
424B5
TRIL
Trillium Therapeutics Inc.
9 Sep 20
Prospectus supplement for primary offering
12:00am
6-K
TRIL
Trillium Therapeutics Inc.
9 Sep 20
Current report (foreign)
12:00am
6-K
TRIL
Trillium Therapeutics Inc.
8 Sep 20
Trillium Therapeutics Announces Updated Data from Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies
4:05pm
6-K
TRIL
Trillium Therapeutics Inc.
12 Aug 20
Consolidated Financial Statements
7:04am
6-K
TRIL
Trillium Therapeutics Inc.
30 Jul 20
Trillium Therapeutics Provides Update on Phase 1 Study of TTI-621 and Dose Escalation to 2.0 MG/KG Level
7:29am
6-K
TRIL
Trillium Therapeutics Inc.
6 Jul 20
Current report (foreign)
7:10am